Combined therapy with growth hormone and oxandrolone in adolescent girls with Turner syndrome
P. W. Lu, MB, MM(Syd), Research Fellow in Endocrinology. C. T. Cowell, MB, BS, FRACP, FRCP(C), Senior Paediatric Endocrinologist, Director of Robert Vines Growth Research Centre.
Abstract
Five adolescent girls with Turner syndrome (mean age 13.9 years, mean bone age 12.0 years) were treated with both recombinant human growth hormone (rhGH) and oxandrolone for 2 years with an average increment in height of 13.4 cm. The mean bone age advanced by only 1.2 years, providing an increase in the mean estimated mature height of 9.2 cm. We conclude that rhGH and oxandrolone benefit older teenagers with Turner syndrome because of an increased growth rate with slow progression of skeletal maturation.